CN103554082B - A kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone - Google Patents
A kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone Download PDFInfo
- Publication number
- CN103554082B CN103554082B CN201310509578.5A CN201310509578A CN103554082B CN 103554082 B CN103554082 B CN 103554082B CN 201310509578 A CN201310509578 A CN 201310509578A CN 103554082 B CN103554082 B CN 103554082B
- Authority
- CN
- China
- Prior art keywords
- compound
- amino
- piperidine
- organic solvent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 68
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 81
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- 239000003960 organic solvent Substances 0.000 claims description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 150000007529 inorganic bases Chemical class 0.000 claims description 16
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- -1 4-amino-1-isoindolone-2-yl Chemical group 0.000 claims description 13
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000002194 synthesizing effect Effects 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 10
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 9
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 9
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 8
- 229960001701 chloroform Drugs 0.000 claims description 8
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000007810 chemical reaction solvent Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 229940116269 uric acid Drugs 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052753 mercury Inorganic materials 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 231100000086 high toxicity Toxicity 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002140 halogenating effect Effects 0.000 abstract 1
- OGMCDJBYZAKJTP-UHFFFAOYSA-N methyl 2-(chloromethyl)-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1CCl OGMCDJBYZAKJTP-UHFFFAOYSA-N 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 26
- 238000003756 stirring Methods 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 239000008346 aqueous phase Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000007605 air drying Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229960004942 lenalidomide Drugs 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 210000004180 plasmocyte Anatomy 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229960003433 thalidomide Drugs 0.000 description 3
- KXCVMIGFIUNCNX-UHFFFAOYSA-N 3-bromooxane-2,6-dione Chemical compound BrC1CCC(=O)OC1=O KXCVMIGFIUNCNX-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- DUEZHSLFTSMAIB-UHFFFAOYSA-N tert-butyl 3-bromo-2,6-dioxopiperidine-1-carboxylate Chemical compound BrC1C(N(C(CC1)=O)C(=O)OC(C)(C)C)=O DUEZHSLFTSMAIB-UHFFFAOYSA-N 0.000 description 2
- 0 *[C@](CCC[C@@](*1N)*=C)[C@]1O Chemical compound *[C@](CCC[C@@](*1N)*=C)[C@]1O 0.000 description 1
- MOQCFMZWVKQBAP-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)benzoyl]-n-(4-chlorophenyl)piperidine-3-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(CCC2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 MOQCFMZWVKQBAP-UHFFFAOYSA-N 0.000 description 1
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SXJBXOSFSVLPNU-PSASIEDQSA-N CC[C@@H](C)C([C@@H](CN(C)C)Cl)=C Chemical compound CC[C@@H](C)C([C@@H](CN(C)C)Cl)=C SXJBXOSFSVLPNU-PSASIEDQSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015094 Paraproteins Human genes 0.000 description 1
- 108010064255 Paraproteins Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to field of medicaments, particularly relate to a kind of pharmaceutical synthesis field, more specifically relate to a kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone.Based on current 3-(4-amino-1-isoindolone-2-base) piperidines-2, 6-diketone suitability for industrialized production difficulty is large, subsequent treatment process is loaded down with trivial details waits deficiency, disclose a kind of synthesis 3-(4-amino-1-isoindolone-2-base newly) piperidines-2, the method of 6-diketone, creatively change traditional preparation method, traditional ring-closure reaction is instead of with halogenating reaction, avoid the use of 2-brooethyl-3-nitro-benzoic acid methyl ester (or 2-chloromethyl-3-nitro-benzoic acid methyl ester), without the need to the use of ultraviolet mercury lamp, it also avoid the use of multiple high toxicity reaction promoter, preparation method is simple, with low cost, be suitable for the requirement of suitability for industrialized production.
Description
Technical Field
The invention relates to the field of medicines, in particular to the field of medicine synthesis, and more particularly relates to a method for synthesizing 3- (4-amino-1-isoindolinone-2-yl) piperidine-2, 6-diketone.
Background
Multiple myeloma is a malignant plasma cell proliferative hematological tumor. The plasma cells having the ability to secrete immunoglobulins
Functionally, but the proliferating plasma cells in most multiple myeloma patients produce only one immunoglobulin protein called accessory protein (paraprotein) or M protein that is not beneficial to the body, and normal plasma cells and other leukocytes are replaced by malignant plasma cells, resulting in reduced synthesis and secretion of normal immunoglobulins. Multiple myeloma cells also invade other tissues of the body, such as bone tissue, and cause tumorigenesis. Multiple myeloma is the second largest hematological neoplasm, with patients accounting for approximately 1% of all neoplastic patients and deaths accounting for approximately 2% of all cancer deaths.
Lenalidomide is a novel immune-regulating non-chemotherapy anti-cancer drug, the chemical components of the lenalidomide are similar to those of thalidomide (thalidomide), but the lenalidomide has a more remarkable curative effect in experimental application, and some side effects frequently caused by taking the thalidomide do not appear.
The literature reports that the route for preparing lenalidomide is generally that 3-aminopiperidine-2, 6-dione hydrochloride is condensed with 2-bromomethyl-3-nitro-methyl benzoate (or 2-chloromethyl-3-nitro-methyl benzoate) and then nitro is reduced into amino to prepare lenalidomide, and different preparation methods are different in the post-treatment process after each reaction.
For example, patent WO2010100476 discloses a process for the preparation of lenalidomide having the chemical reaction formula:
in the reaction, firstly, the raw material 2-bromomethyl-3-nitro-methyl benzoate (or 2-chloromethyl-3-nitro-methyl benzoate) needs to be irradiated under ultraviolet light (mercury lamp) to generate bromination firstly, but the catalytic reaction has long reflux time and low yield, so that the compound is taken as a starting material and industrial production is difficult. Meanwhile, the mercury lamp has harm to human body, so that the labor under ultraviolet light is not beneficial to the labor protection of staff.
Meanwhile, the solvent involved in the reaction is often a highly toxic substance, and the reaction requires a long time of reflux, which is not favorable for industrial production.
Disclosure of Invention
Based on the defects of large difficulty in industrial production, complicated subsequent treatment process and the like of the current 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-diketone, a novel method for synthesizing the 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-diketone is disclosed, and the synthetic route is as follows:
,
wherein X represents a halogen, preferably Cl or Br.
Further, we also disclose in detail, the steps are:
reacting a compound III with a compound IV in an organic solvent of inorganic base to generate a compound II, wherein the reaction temperature is 0-80 ℃;
and step two, converting the compound II into the compound I in an organic solvent environment of ammonia gas or uric acid, wherein the reaction temperature is 80-200 ℃.
Furthermore, in the first step and the second step, any one or any several of the following conditions are preferred:
in the first condition, the inorganic base in the first step is preferably one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate;
secondly, in the first step, the organic solvent is preferably one of N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile and acetone;
and thirdly, the organic solvent in the second step is one of water, ethanol, methanol, tetrahydrofuran, acetonitrile, dichloromethane, pyridine and triethylamine.
Meanwhile, we also disclose a method for synthesizing 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-diketone, and the synthetic route is as follows:
,
wherein R is benzyl, benzyloxycarbonyl, or tert-butoxycarbonyl.
Further, we also disclose in detail, the steps are:
reacting a compound III with a compound IX in an organic solvent of inorganic base to generate a compound VIII, wherein the reaction temperature is 0-80 ℃;
step two, converting the compound VIII into a compound I at the temperature of 20-80 ℃,
wherein,
in the first case, when R is benzyl or benzyloxycarbonyl, the compound is converted into a compound I under the reduction of hydrogen in the presence of palladium-carbon as a catalyst;
and secondly, when R is tert-butyloxycarbonyl, the tert-butyloxycarbonyl is converted into the compound I under the action of a mineral acid solution.
Furthermore, in the first step and the second step, any one or any several of the following conditions are preferred:
in the first condition, the inorganic base in the first step is preferably one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate;
secondly, in the first step, the organic solvent is preferably one of N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile and acetone;
thirdly, in the second step, the reaction solvent is one of water, ethanol, methanol, tetrahydrofuran, acetonitrile, dichloromethane, pyridine and triethylamine;
the fourth condition is that when the first condition in the second step is adopted, the dosage of the catalyst is 5% -10% of the total reaction amount;
and fifthly, when the condition II in the step II is adopted, the inorganic acid is one of hydrochloric acid, sulfuric acid and hydrofluoric acid.
At the same time, we further disclose that the synthetic route of said compound IX is:
wherein R is one of benzyl, carbobenzoxy and tert-butyloxycarbonyl.
Furthermore, the synthesis process of the compound IX is disclosed, wherein the solvent environment of the reaction is an alkaline organic solvent, and the reaction temperature is 20-80 ℃.
Meanwhile, in the synthesis process of the compound IX, we further disclose that the basic organic solvent is an organic solvent of an inorganic base, the inorganic base is preferably one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate, and the organic solvent is preferably one of N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile, acetone and the like, pyridine and triethylamine.
Further, said compound III is replaced by a compound VII,
。
thus two similar synthetic routes are formed, adaptively requiring the conversion of the nitro group in an important intermediate to an amino group.
One of the synthetic routes is as follows:
wherein X also represents Cl, Br, I;
we also disclose in detail, the steps are:
step one, reacting a compound VII with a compound IV in an organic solvent of inorganic base to generate a compound VI, wherein the reaction temperature is 0-80 ℃;
and step two, converting the compound V into a compound I in an organic solvent environment of ammonia gas or uric acid, wherein the reaction temperature is 80-200 ℃.
Furthermore, in the first step and the second step, any one or any several of the following conditions are preferred:
in the first condition, the inorganic base in the first step is preferably one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate;
secondly, in the first step, the organic solvent is preferably one of N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile and acetone;
and thirdly, the organic solvent in the second step is one of water, ethanol, methanol, tetrahydrofuran, acetonitrile, dichloromethane, pyridine and triethylamine.
The other synthetic route is as follows:
;
we also disclose in detail, the steps are:
reacting a compound VII with a compound IX in an organic solvent of inorganic base to generate a compound X, wherein the reaction temperature is 0-80 ℃;
step two, converting the compound X into a compound I at the temperature of 20-80 ℃,
wherein,
in the first case, when R is benzyl or benzyloxycarbonyl, the compound is converted into a compound I under the reduction of hydrogen in the presence of palladium-carbon as a catalyst;
and secondly, when R is tert-butyloxycarbonyl, the tert-butyloxycarbonyl is converted into the compound I under the action of a mineral acid solution.
Furthermore, in the first step and the second step, any one or any several of the following conditions are preferred:
in the first condition, the inorganic base in the first step is preferably one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate;
secondly, in the first step, the organic solvent is preferably one of N, N-dimethylformamide, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile and acetone;
thirdly, in the second step, the reaction solvent is one of water, ethanol, methanol, tetrahydrofuran, acetonitrile, dichloromethane, pyridine and triethylamine;
the fourth condition is that when the first condition in the second step is adopted, the dosage of the catalyst is 5% -10% of the total reaction amount;
and fifthly, when the condition II in the step II is adopted, the inorganic acid is one of hydrochloric acid, sulfuric acid, hydrofluoric acid and hydrobromic acid.
The traditional preparation method is creatively changed, the traditional cyclization reaction is replaced by the halogenation reaction, the use of 2-bromomethyl-3-nitro-methyl benzoate (or 2-chloromethyl-3-nitro-methyl benzoate) is avoided, the use of an ultraviolet mercury lamp is not needed, and the use of various high-toxicity reaction aids is also avoided, so that the preparation method is simple, the cost is low, and the preparation method is suitable for the requirements of industrial production.
Meanwhile, the reaction conditions of each stage are mild, and harsh long-time reflux reaction is not needed.
Furthermore, according to the preparation process disclosed by the invention, the purity of the target product after reaction in each step is high, and complicated post-treatment steps are not needed.
The target compound can be quickly obtained only by two steps, the synthetic route is short, and the method is simple and convenient.
Meanwhile, the solvent used in the reaction of each stage is environment-friendly.
Detailed Description
Example 1
3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione
1) Under the protection of nitrogen, 14.8g of compound III, 50ml of N-methylpyrrolidone, 14g of potassium carbonate and 20g of bromoglutaric anhydride were added to a reaction flask, and the mixture was reacted overnight at 25 ℃ with stirring. The solid was filtered off, and the reaction solution was concentrated under reduced pressure to give 25 g. The yield thereof was found to be 96%.
2) 13g of compound II and 4g of urea were added to a reaction flask under nitrogen protection, and reacted at 180 ℃ for 3 hours with stirring. Adding 80ml of acetonitrile and 30ml of dimethyl sulfoxide into the system, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 9g of off-white solid with the yield of 69%.
Example 2
3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione
1) Under nitrogen protection, 14.8g of compound III, 50ml of N, N-dimethylformamide and 14g of potassium carbonate, 30g of 1-benzyl-3-bromopiperidine-2, 6-dione were added to a reaction flask, and the mixture was reacted overnight at 80 ℃ with stirring. 75ml of water and 150ml of methylene chloride were added, the aqueous phase was discarded, and the organic phase was extracted with 2mol/L hydrochloric acid. 150ml of dichloromethane was added to the aqueous hydrochloric acid solution, sodium carbonate was added until the pH of the aqueous phase became =7, the organic phase was taken out, dried over anhydrous sodium sulfate, and the mother liquor was concentrated under reduced pressure to dryness to obtain 30g of compound VIII with a yield of 86%.
2) Adding 5g of compound VIII (wherein R is benzyl) and 100mL of methanol into a reaction bottle, stirring, adding 0.25g of 10% palladium carbon, vacuumizing the solution to obtain gray turbid solution, performing N2 replacement three times, H2 replacement three times, performing normal pressure hydrogenation, keeping the temperature at 25-30 ℃ for reaction for 41 hours, monitoring the reaction by TLC (thin layer chromatography), filtering the reaction solution, and concentrating the filtrate to dryness to obtain 3.5g of off-white solid. Adding 30ml of acetonitrile and 9ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 3.2g of off-white solid with the yield of 87%.
Example 3
3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione
1) Under nitrogen protection, 14.8g of compound III, 50ml of N, N-dimethylformamide, 14g of potassium carbonate, and 35g of 1-benzyloxycarbonyl-3-bromopiperidine-2, 6-dione were charged into a reaction flask, and the mixture was reacted overnight at 80 ℃ with stirring. 75ml of water and 150ml of methylene chloride were added, the aqueous phase was discarded, and the organic phase was extracted with 2mol/L hydrochloric acid. 150ml of dichloromethane was added to the aqueous hydrochloric acid solution, sodium carbonate was added until the pH of the aqueous phase became =7, the organic phase was taken out, dried over anhydrous sodium sulfate, and the mother liquor was concentrated under reduced pressure to dryness to obtain 30g of compound VIII with a yield of 86%.
2) Adding 5.6g of compound VIII (wherein R is benzyloxycarbonyl) and 100mL of methanol into a reaction bottle, stirring, adding 0.25g of 10% palladium carbon, vacuumizing the solution to obtain grey turbid solution, performing N2 replacement three times, performing H2 replacement three times, hydrogenating at normal pressure, keeping the temperature at 25-30 ℃ for 41 hours, monitoring by TLC (thin layer chromatography) after the reaction is completed, filtering, and concentrating the filtrate to dryness to obtain 3.5g of an off-white solid. Adding 30ml of acetonitrile and 9ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 3.0g of off-white solid with the yield of 83%.
Example 4
1) Under nitrogen protection, 14.8g of compound III, 50ml of N, N-dimethylformamide, 14g of potassium carbonate, and 32g of 1-tert-butoxycarbonyl-3-bromopiperidine-2, 6-dione were charged in a reaction flask, and the mixture was reacted overnight at 80 ℃ with stirring. 75ml of water and 150ml of methylene chloride were added, the aqueous phase was discarded, and the organic phase was extracted with 2mol/L hydrochloric acid. 150ml of dichloromethane was added to the aqueous hydrochloric acid solution, sodium carbonate was added until the pH of the aqueous phase became =7, the organic phase was taken out, dried over anhydrous sodium sulfate, and the mother liquor was concentrated under reduced pressure to dryness to obtain 30g of compound VIII with a yield of 86%.
2) 5g of compound VIII (wherein R is tert-butyloxycarbonyl), 20mL of dichloromethane and 20mL of trifluoroacetic acid were added to a reaction flask, and after completion of the reaction was monitored by TLC, the reaction solution was concentrated to dryness to obtain 3.4g of an off-white solid. Adding 30ml of acetonitrile and 9ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 3.0g of off-white solid with the yield of 83%.
Example 5
Under nitrogen protection, 19g of compound XI, 50ml of N, N-dimethylformamide, 14g of potassium carbonate and 25g of benzyl bromide were added to a reaction flask, and the mixture was reacted overnight at 80 ℃ with stirring. The solid was filtered off, and the reaction solution was concentrated under reduced pressure to obtain 27 g. The yield thereof was found to be 96%.
The substituted pattern of benzyloxycarbonyl and t-butoxycarbonyl groups is the same as that of benzyl group in this reaction, and can be prepared by the methods described above, and will not be described redundantly.
Example 6
1) Under the protection of nitrogen, 17.8g of compound VII, 50ml of N, N-dimethylformamide, 14g of potassium carbonate and 20g of bromoglutaric anhydride were charged into a reaction flask, and reacted overnight at 75 ℃ with stirring. The solid was filtered off, and the reaction solution was concentrated under reduced pressure to give 26 g. The yield thereof was found to be 90%.
2) Under nitrogen protection, 14.5g of compound VI and 200mL of ammonia ethanol (containing 17g of ammonia) were added to a reaction flask, and the mixture was reacted overnight at 50 ℃ with stirring. The reaction solution was concentrated under reduced pressure to obtain 14g of Compound V, yield: 97%.
3) Adding 5g of compound V and 100mL of methanol into a reaction bottle, stirring, adding 0.25g of 10% palladium carbon, enabling the solution to be grey turbid, vacuumizing, performing N2 replacement three times, performing H2 replacement three times, hydrogenating at normal pressure, preserving the temperature at 25-30 ℃ for 41H, enabling the solution to slowly turn black from grey during the reaction, monitoring by TLC (thin layer chromatography) after the reaction is completed, filtering, and concentrating the filtrate to be dry to obtain 4.4g of off-white solid. Adding 30ml of acetonitrile and 9ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 3g of off-white solid with the yield of 67%.
Example 7
1) Under nitrogen protection, 17.8g of compound VII, 50ml of N, N-dimethylformamide, 14g of potassium carbonate, 30g of 1-benzyl-3-bromopiperidine-2, 6-dione were charged in a reaction flask, and reacted overnight at 80 ℃ with stirring. 75ml of water and 150ml of methylene chloride were added, the aqueous phase was discarded, and the organic phase was extracted with 2mol/L hydrochloric acid. Further, 150ml of methylene chloride was added to the aqueous hydrochloric acid solution, sodium carbonate was added to adjust the pH of the aqueous phase to =7, the organic phase was taken out, dried over anhydrous sodium sulfate, and the mother liquor was concentrated under reduced pressure to dryness to obtain 33g of compound X with a yield of 87%.
2) Adding 5g of compound X (wherein R is benzyl) and 100mL of methanol into a reaction bottle, stirring, adding 0.25g of 10% palladium carbon, vacuumizing the solution to obtain gray turbid solution, performing N2 replacement three times, H2 replacement three times, performing normal pressure hydrogenation, keeping the temperature at 25-30 ℃ for reaction for 41 hours, monitoring the reaction by TLC (thin layer chromatography), filtering the reaction solution, and concentrating the filtrate to dryness to obtain 3.1g of an off-white solid. Adding 25ml of acetonitrile and 7ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 2.8g of off-white solid with the yield of 82%.
Example 8
1) Under nitrogen protection, 17.8g of compound VII, 50ml of N, N-dimethylformamide, 14g of potassium carbonate, and 35g of 1-benzyloxycarbonyl-3-bromopiperidine-2, 6-dione were charged into a reaction flask, and the mixture was reacted overnight at 80 ℃ with stirring. 75ml of water and 150ml of methylene chloride were added, the aqueous phase was discarded, and the organic phase was extracted with 2mol/L hydrochloric acid. Further, 150ml of methylene chloride was added to the aqueous hydrochloric acid solution, sodium carbonate was added to adjust the pH of the aqueous phase to =7, the organic phase was taken out, dried over anhydrous sodium sulfate, and the mother liquor was concentrated under reduced pressure to dryness to obtain 36g of compound X with a yield of 86%.
2) Adding 5g of compound X (wherein R is benzyloxycarbonyl) and 100mL of methanol into a reaction bottle, stirring, adding 0.25g of 10% palladium carbon, vacuumizing the solution to obtain gray turbid solution, performing N2 replacement three times, performing H2 replacement three times, performing normal pressure hydrogenation, keeping the temperature at 25-30 ℃ for reaction for 41 hours, monitoring the reaction by TLC (thin layer chromatography), filtering the reaction solution after the reaction is completed, and concentrating the filtrate to dryness to obtain 3.1g of an off-white solid. Adding 25ml of acetonitrile and 7ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 2.5g of off-white solid with the yield of 81%.
Example 9
1) Under nitrogen protection, 17.8g of compound VII, 50ml of N, N-dimethylformamide, 14g of potassium carbonate, and 32g of 1-tert-butoxycarbonyl-3-bromopiperidine-2, 6-dione were charged in a reaction flask, and the mixture was reacted overnight at 80 ℃ with stirring. 75ml of water and 150ml of methylene chloride were added, the aqueous phase was discarded, and the organic phase was extracted with 2mol/L hydrochloric acid. Further, 150ml of methylene chloride was added to the aqueous hydrochloric acid solution, sodium carbonate was added to adjust the pH of the aqueous phase to =7, the organic phase was taken out, dried over anhydrous sodium sulfate, and the mother liquor was concentrated under reduced pressure to dryness to obtain 33g of compound X with a yield of 85%.
2) Adding 5g of compound X (wherein R is tert-butyloxycarbonyl) into a reaction bottle, stirring 100mL of methanol, 10mL of trifluoromethanesulfonic acid, adding 0.25g of 10% palladium carbon, wherein the solution is grey turbid, vacuumizing, replacing three times with N2, replacing three times with H2, hydrogenating under normal pressure, keeping the temperature at 25-30 ℃ for 41 hours, monitoring by TLC after the reaction is completed, filtering, and concentrating the filtrate to dryness to obtain 3.1g of off-white solid. Adding 25ml of acetonitrile and 7ml of dimethyl sulfoxide, stirring for 1h at 70-80 ℃, cooling to room temperature, carrying out suction filtration, and carrying out forced air drying on the solid at 100 ℃ to obtain 2.7g of off-white solid with the yield of 82%.
Claims (12)
1. A method for synthesizing 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-diketone, which is characterized in that the synthetic route is as follows:
wherein X represents a halogen.
2. The method for synthesizing 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-dione as claimed in claim 1, wherein the halogen is Cl or Br.
3. The process of claim 1 for the synthesis of 3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione, comprising the steps of:
reacting a compound III with a compound IV in an organic solvent of inorganic base to generate a compound II, wherein the reaction temperature is 0-80 ℃;
and step two, converting the compound II into the compound I in an organic solvent environment of ammonia gas or uric acid, wherein the reaction temperature is 80-200 ℃.
4. The method for synthesizing 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-dione as claimed in claim 3, further comprising one or more of the following conditions:
in the first step, the inorganic base is one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate;
secondly, in the first step, the organic solvent is one of N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile and acetone;
and thirdly, the organic solvent in the second step is one of water, ethanol, methanol, tetrahydrofuran, acetonitrile, dichloromethane, pyridine and triethylamine.
5. A method for synthesizing 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-diketone, which is characterized in that the synthetic route is as follows:
wherein R is benzyl, benzyloxycarbonyl, or tert-butoxycarbonyl.
6. The process of claim 5 for the synthesis of 3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione, comprising the steps of:
reacting a compound III with a compound IX in an organic solvent of inorganic base to generate a compound VIII, wherein the reaction temperature is 0-80 ℃;
step two, converting the compound VIII into a compound I at the temperature of 20-80 ℃,
wherein,
in the first case, when R is benzyl or benzyloxycarbonyl, the compound is converted into a compound I under the reduction of hydrogen in the presence of palladium-carbon as a catalyst;
and secondly, when R is tert-butyloxycarbonyl, the tert-butyloxycarbonyl is converted into the compound I under the action of a mineral acid solution.
7. The method for synthesizing 3- (4-amino-1-isoindolone-2-yl) piperidine-2, 6-dione according to claim 6, further comprising one or more of the following conditions:
in the first step, the inorganic base is one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate;
secondly, in the first step, the organic solvent is one of N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, trichloromethane, tetrahydrofuran, acetonitrile and acetone;
thirdly, in the second step, the reaction solvent is one of water, ethanol, methanol, tetrahydrofuran, acetonitrile, dichloromethane, pyridine and triethylamine;
the fourth condition is that when the first condition in the second step is adopted, the dosage of the catalyst is 5-10% of the total reaction amount;
and fifthly, when the condition II in the step II is adopted, the inorganic acid is one of hydrochloric acid, sulfuric acid and hydrofluoric acid.
8. The process for the synthesis of 3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione, according to claim 5, characterized by the fact that the synthesis route of compound IX is:
wherein R is one of benzyl, carbobenzoxy and tert-butyloxycarbonyl.
9. The method for synthesizing 3- (4-amino-1-isoindolinone-2-yl) piperidine-2, 6-dione as claimed in claim 8, wherein the solvent environment for the reaction is a basic organic solvent, and the reaction temperature is 20-80 ℃.
10. The method for synthesizing 3- (4-amino-1-isoindolinone-2-yl) piperidine-2, 6-dione as claimed in claim 9, wherein the basic organic solvent is an organic solvent of an inorganic base.
11. The method according to claim 10, wherein the inorganic base is one of potassium hydroxide, potassium carbonate, sodium hydroxide, sodium carbonate and cesium carbonate, and the organic solvent is one of N, N-dimethylformamide, N-methylpyrrolidone, dimethylsulfoxide, dichloromethane, chloroform, tetrahydrofuran, acetonitrile, acetone, etc., pyridine and triethylamine.
12. The process for the synthesis of 3- (4-amino-1-isoindolon-2-yl) piperidine-2, 6-dione as claimed in claim 1 or 5, wherein said compound III is replaced by compound VII,
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310509578.5A CN103554082B (en) | 2013-10-25 | 2013-10-25 | A kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310509578.5A CN103554082B (en) | 2013-10-25 | 2013-10-25 | A kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103554082A CN103554082A (en) | 2014-02-05 |
CN103554082B true CN103554082B (en) | 2015-12-02 |
Family
ID=50008485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310509578.5A Active CN103554082B (en) | 2013-10-25 | 2013-10-25 | A kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103554082B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107488167A (en) * | 2017-09-29 | 2017-12-19 | 青岛辰达生物科技有限公司 | A kind of preparation method of antineoplastic lenalidomide intermediate |
-
2013
- 2013-10-25 CN CN201310509578.5A patent/CN103554082B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103554082A (en) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018365174B2 (en) | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives | |
CN108586356B (en) | Ribociclib new intermediate and synthetic method for preparing Ribociclib by using same | |
JP7017801B2 (en) | Inhibition of CREB-binding protein (CBP) | |
CN114891004B (en) | Preparation method of sitagliptin intermediate compound | |
KR102303092B1 (en) | Method for producing synthetic pentapeptide | |
CN107810189B (en) | Process for the preparation of nitrogen mustard derivatives | |
CN109678840B (en) | Preparation method of pomalidomide | |
AU2001292386B2 (en) | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | |
CN105198821A (en) | Preparation method of Rociletinib | |
CN103554082B (en) | A kind of synthesis 3-(4-amino-1-isoindolone-2-base) method of piperidines-2,6-diketone | |
CN103193763B (en) | A kind of preparation method of Revlimid | |
CN114671867B (en) | Preparation method of tocartinib intermediate 7-hydroxy- [1,2,4] triazolo [1,5-a ] pyridine | |
KR20210080373A (en) | Methods for preparing solid forms of BET bromodomain inhibitors | |
EP2530077B1 (en) | Novel method for preparing imatinib base | |
CN111349045A (en) | Synthetic method of lenvatinib and novel intermediate | |
US9688685B2 (en) | Method for preparing volasertib and intermediate thereof | |
JP6858762B2 (en) | Salt type, crystalline form of 4H-pyrazolo [1,5-α] benzimidazole compound, and its production method and intermediate. | |
US9115130B2 (en) | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives | |
CN106518939B (en) | Method for preparing Solithromycin compound | |
CN105523958B (en) | A kind of method for preparing Diarylthiohydantoin derivative key intermediate | |
CN109761959B (en) | Method for synthesizing Abemaciclib mesylate | |
CN108101892B (en) | Chrysin non-natural amino acid derivative and preparation method and application thereof | |
CN107602454B (en) | Sulfonamide compound and preparation method and application thereof | |
CN102153518A (en) | Preparation method of Gefitinib | |
CN111051289A (en) | Protected L-carnosine derivative, L-carnosine and method for producing crystalline L-carnosine zinc complex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |